Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer
- PMID: 22934847
- DOI: 10.2174/1566524011313040005
Glutaminase isoenzymes as key regulators in metabolic and oxidative stress against cancer
Abstract
Cancer cells require a robust supply of reduced nitrogen to produce nucleotides, non-essential amino acids and a high cellular redox activity. Glutamine provides a major substrate for respiration as well as nitrogen for the production of proteins, hexosamines, and macromolecules. Therefore, glutamine is one of key molecules in cancer metabolism during cell proliferation. The notion of targeting glutamine metabolism in cancer, originally rationalized by the number of pathways fed by this nutrient, has been reinforced by more recent studies demonstrating that its metabolism is regulated by oncogenes. Glutamine can exert its effects by modulating redox homeostasis, bioenergetics, nitrogen balance or other functions, including by being a precursor of glutathione, the major nonenzymatic cellular antioxidant. Glutaminase (GA) is the first enzyme that converts glutamine to glutamate, which is in turn converted to alpha-ketoglutarate for further metabolism in the tricarboxylic acid cycle. Different GA isoforms in mammals are encoded by two genes, Gls and Gls2. As each enzymatic form of GA has distinct kinetic and molecular characteristics, it has been speculated that the differential regulation of GA isoforms may reflect distinct functions or requirements in different tissues or cell states. GA encoded by Gls gene (GLS) has been demonstrated to be regulated by oncogenes and to support tumor cell growth. GA encoded by Gls2 gene (GLS2) reduces cellular sensitivity to reactive oxygen species associated apoptosis possibly through glutathione-dependent antioxidant defense, and therefore to behave more like a tumor suppressor. Thus, modulation of GA function may be a new therapeutic target for cancer treatment.
Similar articles
-
Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells.J Mol Med (Berl). 2014 Mar;92(3):277-90. doi: 10.1007/s00109-013-1105-2. Epub 2013 Nov 26. J Mol Med (Berl). 2014. PMID: 24276018 Free PMC article.
-
Glutaminases regulate glutathione and oxidative stress in cancer.Arch Toxicol. 2020 Aug;94(8):2603-2623. doi: 10.1007/s00204-020-02838-8. Epub 2020 Jul 18. Arch Toxicol. 2020. PMID: 32681190 Review.
-
Glutaminase isoenzymes in the metabolic therapy of cancer.Biochim Biophys Acta Rev Cancer. 2018 Dec;1870(2):158-164. doi: 10.1016/j.bbcan.2018.07.007. Epub 2018 Jul 24. Biochim Biophys Acta Rev Cancer. 2018. PMID: 30053497 Review.
-
The role of glutaminase in cancer.Histopathology. 2020 Mar;76(4):498-508. doi: 10.1111/his.14014. Epub 2020 Feb 18. Histopathology. 2020. PMID: 31596504 Review.
-
GLS and GLS2 Glutaminase Isoenzymes in the Antioxidant System of Cancer Cells.Antioxidants (Basel). 2024 Jun 20;13(6):745. doi: 10.3390/antiox13060745. Antioxidants (Basel). 2024. PMID: 38929183 Free PMC article. Review.
Cited by
-
An Update on the Metabolic Landscape of Oncogenic Viruses.Cancers (Basel). 2022 Nov 23;14(23):5742. doi: 10.3390/cancers14235742. Cancers (Basel). 2022. PMID: 36497226 Free PMC article. Review.
-
Identification and characterization of a novel glutaminase inhibitor.FEBS Open Bio. 2022 Jan;12(1):163-174. doi: 10.1002/2211-5463.13319. Epub 2021 Nov 8. FEBS Open Bio. 2022. PMID: 34698439 Free PMC article.
-
Multiomics Analysis Reveals that GLS and GLS2 Differentially Modulate the Clinical Outcomes of Cancer.J Clin Med. 2019 Mar 13;8(3):355. doi: 10.3390/jcm8030355. J Clin Med. 2019. PMID: 30871151 Free PMC article.
-
The molecular rationale for therapeutic targeting of glutamine metabolism in pulmonary hypertension.Expert Opin Ther Targets. 2019 Jun;23(6):511-524. doi: 10.1080/14728222.2019.1615438. Epub 2019 May 11. Expert Opin Ther Targets. 2019. PMID: 31055988 Free PMC article. Review.
-
Metabolic Reprogramming in Metastatic Melanoma with Acquired Resistance to Targeted Therapies: Integrative Metabolomic and Proteomic Analysis.Cancers (Basel). 2020 May 22;12(5):1323. doi: 10.3390/cancers12051323. Cancers (Basel). 2020. PMID: 32455924 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous